Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
5 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Gastrointestinal bleeding tied to poorer outcomes in STEMI patients

18 Jul 2019

While gastrointestinal bleeding (GIB) is uncommon among patients with ST-elevation myocardial infarction (STEMI), the complication leads to greater morbidity, mortality and resource utilization, reports a new study.

The study included 1,450,696 STEMI patients, of which only 2.2 percent (n=32,624) were complicated with GIB. The incidence rate of GIB in STEMI decreased over time, going from 2.7 percent in the year 2003 to 2.0 percent in 2016 (p-trend<0.001). Those with GIB were older (73±14 vs 68±15 years; p<0.001) and were more likely to be female (44.9 percent vs 36.8 percent; p<0.001).

Compared with patients who did not develop the complication, those with GIB had significantly higher incidence rates of in-hospital mortality (28.2 percent vs 11.1 percent; p<0.001), acute kidney injury (29.8 percent vs 11.0 percent; p<0.001) and stroke (3.5 percent vs 1.5 percent; p<0.001).

In addition, patients with GIB were also more likely to need blood transfusion (29.3 percent vs 5.8 percent; p<0.001) and new dialysis requirements (2.5 percent vs 0.7 percent; p<0.001), and were less likely to be discharged from the hospital (nondischarge: 41.5 percent vs 25.8 percent; p<0.001).

Median length of stay (6 vs 3 days; p<0.001) as well as mean cost (USD 30,752±42,802 vs 21,372±23,552; p<0.001) were similarly significantly higher in patients who developed GIB.

“To our knowledge, this is the largest nationwide analysis examining the incidence and outcomes of GIB in patients admitted with STEMI,” said researchers. “[W]e believe that this study offers important insights into a high-risk cohort of patients in whom data to guide optimal therapy are scarce.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
5 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.